TROPION-Lung01 Study Design and Baseline demographics
Daiichi-Sankyo
Conclusions
•
•
•
•
R-DXd is the first CDH6-directed ADC to demonstrate promising efficacy in patients with heavily
pretreated platinum-resistant OVC who were not selected based on tumor CDH6 expression
。 ORR: 46% in the 4.8-8.0 mg/kg OVC cohort; one CR and 22 PRs
● Median DOR: 11.2 monthsª
。 Median PFS: 7.9 monthsb
Safety profile is manageable, and toxicities are consistent with those observed with other DXd ADCs 1,2
Based on the accumulated overall safety, tolerability, PK and efficacy profile of R-DXd, the 8.0 mg/kg
cohort was closed, and further assessment is ongoing at three dose levels: 4.8 mg/kg, 5.6 mg/kg
and 6.4 mg/kg
These data support further clinical evaluation of R-DXd in a late-phase study in patients with OVC
*Median follow-up for DOR: 5.8 months (range: 1.4-16.8). "Median follow-up for PFS: 5.6 months (range: 0.03-25.1).
ADC, antibody-drug conjugate; CDH8, cadherin 8; CI, confidence interval; CR, complete response; DOR, duration of response; DXd, deruxtecan;
ORR, objective response rate; OVC, ovarian cancer; PFS, progression-free survival; PK, pharmacokinetics; PR, partial response.
1. Guo Z, et al. J Clin Pham Ther 2022:47:1837-1844; 2. Jänne PA, et al. Cancer Discov. 2022;12:74-89.
59
59View entire presentation